Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies
Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Both immunotherapy (IO) and targeted therapy (TT) are used as adjuvant (adj) treatment for stage III melanoma, however, data describing real‐world outcomes are limited. In addition, a significant proportion of patients relapse, for whom best management is unclear. The aim of our study was to assess the efficacy, and safety of adj anti...
Alternative Titles
Full title
Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_00d7e2c1a4e64eb7bb23bb9111e3990d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_00d7e2c1a4e64eb7bb23bb9111e3990d
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.7257
